2024
Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse events
2023
Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Abstract 13931: Comparison of Inpatient Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid versus Tricuspid Aortic Valve Stenosis: An Insight From National Inpatient Sample
Poudyal A, Park D, Khanal S, Shrestha P, Sharma B, Karki S, Vij A. Abstract 13931: Comparison of Inpatient Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid versus Tricuspid Aortic Valve Stenosis: An Insight From National Inpatient Sample. Circulation 2022, 146: a13931-a13931. DOI: 10.1161/circ.146.suppl_1.13931.Peer-Reviewed Original ResearchTricuspid aortic valve patientsBicuspid aortic valvePermanent pacemaker placementTricuspid aortic valveLength of hospital stayBicuspid aortic valve patientsNo significant differenceParavalvular leakEmbolic strokePropensity score matchingAortic stenosisSignificant differenceAortic valveOutcomes of transcatheter aortic valve replacementTricuspid aortic valve groupTricuspid aortic valve stenosisLong-term follow-upTranscatheter aortic valve replacementRate of embolic strokeAortic valve anatomyScore matchingAortic valve replacementSevere aortic stenosisAortic valve stenosisNational Inpatient Sample databaseAbstract 15751: Trends and Disparities in Pulmonary Arterial Hypertension Over the Past Decade: A National Inpatient Sample Database Study
Sana M, ASEMOTA I, Park D, Hammo H, Yilmaz M, Murthi M, Sharma B, Shaka H. Abstract 15751: Trends and Disparities in Pulmonary Arterial Hypertension Over the Past Decade: A National Inpatient Sample Database Study. Circulation 2022, 146: a15751-a15751. DOI: 10.1161/circ.146.suppl_1.15751.Peer-Reviewed Original ResearchDiagnosis of pulmonary arterial hypertensionPulmonary arterial hypertensionMedian household incomePrincipal diagnosisLength of hospital stayArterial hypertensionCrude admission ratesNo significant differenceInpatient mortality rateRate of pulmonary arterial hypertensionRisk of pulmonary arterial hypertensionAssociated with increased riskOutcome analysisNational Inpatient Sample databasePrimary outcome analysisSecondary outcome analysisAsian/Pacific IslanderSignificant differenceInpatient Sample databaseAdult hospitalsInpatient mortalityICD-9Household incomeCalendar yearAfrican AmericansAbbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis
Park D, An S, Kumar A, Malhotra S, Jolly N, Kaur A, Kattoor A, Doukky R, Kalra A, Vij A. Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. American Journal Of Cardiovascular Drugs 2022, 22: 633-645. PMID: 35781867, DOI: 10.1007/s40256-022-00541-w.Peer-Reviewed Original ResearchConceptsNet adverse clinical eventsDuration of DAPTPercutaneous coronary interventionNetwork meta-analysisShorter duration of DAPTStent thrombosisMyocardial infarctionDrug-eluting stentsMeta-analysisResultsSeventeen randomized controlled trialsSystematic reviewAdverse cardiac eventsAdverse clinical eventsFrequentist network meta-analysesRisk of myocardial infarctionBackgroundDual antiplatelet therapyMonths of DAPTRandomized controlled trialsRandom-effects modelNetwork meta-analysesClinical presentationNo significant differenceAntiplatelet therapyMethodsThe present studyCardiac events